临床研究
Copyright ©The Author(s) 2023.
世界华人消化杂志. 2023-05-08; 31(9): 377-384
在线出版 2023-05-08. doi: 10.11569/wcjd.v31.i9.377
表1 200例患者治疗情况
病情分类例数无肝损伤完成抗结核标准疗程有肝损伤完成抗结核标准疗程肺结核治疗失败
HBsAg
阳性8626(30.23)41(47.67)19(22.09)
阴性11477(67.54)28(24.56)9(7.89)
χ227.32211.5898.208
P<0.0010.0010.004
肝组织炎症坏死分级
G16452(81.25)12(18.75)0(0.00)
G27138(53.52)23(32.39)10(14.08)
G36513(20.00)34(52.31)18(27.69)
χ248.61616.28620.540
P<0.0010.0010.004
肝组织纤维化程度
S04641(89.13)5(10.87)0(0.00)
S14833(68.75)14(29.17)1(2.08)
S25626(46.43)21(37.50)9(16.07)
S3503(6.00)29(58.00)18(36.00)
χ273.81624.41333.449
P<0.001<0.001<0.001
表2 200例患者肝损伤总体情况
肝生化轻度异常中度异常重度异常总异常率
ALT16(8.00)17(8.50)3(1.50)36(18.00)
AST20(10.00)25(12.50)4(2.00)45(22.50)
胆碱酯酶5(2.50)3(1.50)2(1.00)10(5.00)
凝血酶原活动度21(10.50)5(2.50)1(0.50)27(13.50)
电泳γ球蛋白13(6.50)6(3.00)2(1.00)21(10.50)
A/G15(7.50)2(1.00)1(0.50)18(9.00)
白蛋白9(4.50)4(2.00)1(0.50)14(7.00)
总胆红素22(11.00)13(6.50)4(2.00)39(34.50)
表3 不同病情患者治疗前后肝生化变化
病情分类例数ALT(U/L)AST(U/L)胆碱酯酶(U/L)凝血酶原活动度(%)电泳γ球蛋白(%)A/G白蛋白(g/L)总胆红素
HBsAg
阳性8630.15±4.0632.80±3.775824.06±317.3383.66±7.5215.42±3.031.82±0.2442.25±6.0813.05±3.42
阴性11429.87±4.2931.95±4.165872.82±325.9784.78±8.9415.75±3.481.86±0.2743.19±5.6412.79±3.55
t0.4681.4891.0590.9380.7011.0871.1280.521
P0.6410.1380.2910.3490.4840.2780.2610.603
肝组织炎症坏死分级
G16429.79±3.7931.00±3.885887.60±309.6485.01±9.5715.73±3.501.83±0.2543.05±5.7512.94±3.61
G27129.35±4.0532.27±4.365824.35±348.1184.18±8.6815.90±3.261.82±0.2642.97±6.2212.86±3.49
G36530.89±4.6332.67±4.195846.69±326.7483.73±9.0315.18±3.471.87±0.2442.34±5.9412.90±3.52
F2.4242.8470.6330.3300.8150.7430.2770.009
P0.0910.0600.5320.7200.4440.4770.7590.991
肝组织纤维化程度
S04629.16±3.7631.76±3.595834.22±316.2083.66±8.7715.77±3.601.86±0.2342.88±6.0312.88±3.40
S14829.85±4.5132.45±3.765909.75±309.7984.95±9.2515.26±3.391.82±0.2043.01±5.6613.01±3.29
S25630.48±3.8932.68±3.445874.48±338.7683.57±9.8416.03±3.451.83±0.2542.95±5.9212.97±3.34
S35030.34±4.1432.31±3.025787.14±325.6085.08±8.1215.33±3.221.85±0.2742.32±5.8912.73±3.81
F1.0450.6281.3160.4050.5960.2790.1470.064
P0.3740.5980.2700.7500.6180.8400.9320.979
表4 不同病情患者治疗后肝生化变化
病情分类例数ALT(U/L)AST(U/L)胆碱酯酶(U/L)凝血酶原活动度(%)电泳γ球蛋白(%)A/G白蛋白(g/L)总胆红素
HBsAg
阳性8670.52±16.2983.26±20.775400.96±266.0173.22±9.0023.35±3.791.29±0.2236.27±4.5948.94±11.03
阴性11446.88±14.5651.24±18.355696.24±215.3678.84±7.1519.16±4.051.57±0.2639.68±3.0032.76±10.25
t10.79911.5418.6714.9217.4458.0476.34010.695
P<0.001<0.001<0.001<0.001<0.001<0.001<0.001<0.001
肝组织炎症坏死分级
G16440.89±15.0051.71±14.685796.25±208.4478.92±7.0518.04±3.111.60±0.1940.22±3.5620.55±5.00
G27155.74±12.0268.49±17.905532.61±223.3876.84±6.4421.06±3.451.52±0.2138.05±3.6431.04±4.82
G36574.39±16.9574.30±16.115385.83±216.7073.50±6.6323.73±3.671.23±0.1836.41±3.2868.08±4.63
F83.96633.30559.51310.76344.67165.36119.2141747.785
P<0.001<0.001<0.001<0.001<0.001<0.001<0.001<0.001
肝组织纤维化程度
S04642.62±10.0647.55±10.645730.15±197.5880.95±7.1118.11±2.991.70±0.1940.02±4.3925.26±3.85
S14849.98±13.6758.36±13.825694.33±220.3577.78±5.9420.06±3.541.59±0.1738.98±4.5233.85±4.19
S25657.56±11.4668.59±16.675560.72±205.1875.51±6.3821.78±3.261.36±0.2037.84±3.7941.71±5.66
S35076.54±15.9283.45±15.225310.78±184.5071.97±6.5623.53±3.641.19±0.2136.22±4.0556.43±4.94
F61.38354.35443.05216.32622.91568.0527.349373.733
P<0.001<0.001<0.001<0.001<0.001<0.001<0.001<0.001
表5 不同病情患者肝损伤情况
病情分类例数1项异常2项异常≥3项异常总发生率
HBsAg
阳性8624(27.91)20(23.26)16(18.60)60(69.77)
阴性11422(19.30)11(9.65)4(3.51)37(32.46)
χ227.322
P<0.001
肝组织炎症坏死分级
G1648(12.50)4(6.25)0(0.00)12(18.75)
G27117(23.94)11(15.49)5(7.04)33(46.48)
G36521(32.31)16(24.62)15(23.08)52(80.00)
χ248.656
P<0.001
肝组织纤维化程度
S0462(4.35)3(6.52)0(0.00)5(10.87)
S1489(18.75)5(10.42)1(2.08)15(31.25)
S25614(25.00)7(12.50)9(16.07)30(53.57)
S35021(42.00)16(32.00)10(20.00)47(94.00)
χ278.122
P<0.001

引文著录: 田家发, 桂启芳. 不同病情CHB伴肺结核患者抗病毒联合抗结核治疗中肝损伤情况观察及临床意义. 世界华人消化杂志 2023; 31(9): 377-384